Johnson & Johnson board member Dr. Mark McClellan said on Thursday the company plans to have "enough vaccines for 100 million Americans by spring."
"I do know that J&J is making a very large supply, going all out with its production both here in the US and elsewhere around the world, with the goal of having perhaps enough vaccines for 100 million Americans by spring, by this April or so," McClellan told CNBC.
"So that's going to make a big difference in supply availability over the coming weeks and months, if the clinical trial does work out,"
McClellan also said that the vaccine's clinical trial is "going on at very large scale right now" to make sure it's safe and effective.
Close to seeking EUA: Dr. Anthony Fauci said Thursday that Johnson & Johnson is "right around the corner" from seeking emergency use authorization for its Covid-19 vaccine from the FDA.
"Johnson & Johnson is right around the corner ... (which) means that they're probably a couple of weeks away from getting the data looked at, to have the FDA evaluate whether or not we're in a situation where we could move ahead and start thinking about getting it out into the public," Fauci told CNN's Chris Cuomo.
Fauci also stated that the Johnson & Johnson vaccine has some advantages, as it's a single shot, and it doesn't have as stringent of a cold chain requirement.
However, when asked if AstraZeneca is close to requesting an EUA for its vaccine as well, Fauci said they're behind.
"AstraZeneca is not quite there yet, you know that's one that's being tested in multiple countries but it's a bit behind, but not too far behind," Fauci said.